MX2021001288A - Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. - Google Patents

Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.

Info

Publication number
MX2021001288A
MX2021001288A MX2021001288A MX2021001288A MX2021001288A MX 2021001288 A MX2021001288 A MX 2021001288A MX 2021001288 A MX2021001288 A MX 2021001288A MX 2021001288 A MX2021001288 A MX 2021001288A MX 2021001288 A MX2021001288 A MX 2021001288A
Authority
MX
Mexico
Prior art keywords
tumour cells
microvesicles
vaccination
cancer treatment
therapeutic vaccine
Prior art date
Application number
MX2021001288A
Other languages
English (en)
Inventor
Olvera Benjamín Pineda
De La Cruz Verónica Pérez
Original Assignee
Benjamin Pineda Olvera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benjamin Pineda Olvera filed Critical Benjamin Pineda Olvera
Publication of MX2021001288A publication Critical patent/MX2021001288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a microvesículas provenientes de células tumorales naturales y producidas in vitro bajo un estímulo estresor, tal como la radiación, las cuales pueden ser usadas de manera efectiva como vacuna terapéutica para cáncer. También la invención se relaciona con una formulación de vacuna terapéutica que contiene las microvesículas, los procesos para su preparación y a su uso médico como vacuna terapéutica para estimular el sistema inmune antitumoral y tratar el cáncer.
MX2021001288A 2018-07-31 2018-07-31 Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. MX2021001288A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/055740 WO2020026001A1 (es) 2018-07-31 2018-07-31 Vacunación con microvesículas derivadas de células tumorales para tratamiento de cáncer

Publications (1)

Publication Number Publication Date
MX2021001288A true MX2021001288A (es) 2021-07-15

Family

ID=69231505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001288A MX2021001288A (es) 2018-07-31 2018-07-31 Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.

Country Status (6)

Country Link
US (1) US20220008524A1 (es)
EP (1) EP3884958A4 (es)
CN (1) CN113164568A (es)
CA (1) CA3145514A1 (es)
MX (1) MX2021001288A (es)
WO (1) WO2020026001A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134083B (zh) * 2021-03-09 2023-07-07 深圳市人民医院(深圳市呼吸疾病研究所) 声敏剂及其应用
CN114376986B (zh) * 2022-02-25 2023-03-28 南京中医药大学 一种同源重组外泌体多药递送的仿生纳米粒及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514408A (ja) * 1998-05-11 2002-05-21 インセルム（アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 新規アポトーシス小体、それを含有する単球由来細胞、それらの調製方法、及びワクチンとしてのそれらの使用
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
CN103446580B (zh) * 2012-05-31 2016-08-03 湖北盛齐安生物科技有限公司 一种肿瘤疫苗及其制备方法
WO2015157125A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity
CN106139148B (zh) * 2015-04-21 2019-09-10 湖北盛齐安生物科技有限公司 一种肿瘤化疗药物制剂组合
US11053476B2 (en) * 2016-02-23 2021-07-06 Exostem Biotec Ltd. Generation of cancer stem cells and use thereof
WO2018085275A1 (en) * 2016-11-02 2018-05-11 The Regents Of The University Of California Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy

Also Published As

Publication number Publication date
WO2020026001A1 (es) 2020-02-06
EP3884958A1 (en) 2021-09-29
EP3884958A4 (en) 2023-01-25
CA3145514A1 (en) 2020-02-06
CN113164568A (zh) 2021-07-23
US20220008524A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
AU2018256508A1 (en) Individualized vaccines for cancer
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
SG10201900727QA (en) Personalized immunotherapy against several neuronal and brain tumors
WO2016160622A3 (en) Hla-g as a novel target for car t-cell immunotherapy
MX2016014711A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
WO2016025635A3 (en) Combination therapy for treating cancer
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
MX2017013142A (es) Terapia combinada para tratar cáncer.
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2016014367A (es) Combinación de inmunoterapia y radioterapia para el tratamiento de canceres positivos a her-2.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2020006944A (es) Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
GB2534478A (en) Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.